These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 39154154

  • 1. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.
    Sun X, Lyu J, Yang M, Lin Y, Wu K, Liu K, Li A, Shuai X, Cai K, Wang Z, Wang G, Zhang P, Yin Y, Tao K.
    Ann Surg Oncol; 2024 Nov; 31(12):8157-8169. PubMed ID: 39154154
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan XB, Lu CM, Wang JB, Deng WY, Ma YJ, Bie LY, Wang MY, Li J, Xia QX, Wei C, Luo SX.
    Int J Surg; 2024 Apr 01; 110(4):2071-2084. PubMed ID: 38320099
    [Abstract] [Full Text] [Related]

  • 3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD, Zhang H, Dong L, Jiang KW, Ye YJ, Wang S, Zhou J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):145-152. PubMed ID: 33508920
    [Abstract] [Full Text] [Related]

  • 4. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD.
    BMC Cancer; 2020 Sep 15; 20(1):886. PubMed ID: 32933498
    [Abstract] [Full Text] [Related]

  • 5. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, Li X, Wang X, Yuan X.
    Clin Cancer Res; 2020 Sep 01; 26(17):4542-4550. PubMed ID: 32561664
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, Li Z, Lu Y, Zhang J, Zhao K, Zhang Y, Xu N, Li Z, Liu Y, Wang Y, Wang Y, Teng L.
    J Immunother Cancer; 2022 Mar 01; 10(3):. PubMed ID: 35296556
    [Abstract] [Full Text] [Related]

  • 7. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB, Yin YP, Zhang P, Cai M, Chen JH, Li W, Li G, Wang Z, Wang GB, Tao KX.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan 25; 26(1):84-92. PubMed ID: 36650004
    [Abstract] [Full Text] [Related]

  • 8. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J, RESOLVE study group.
    Lancet Oncol; 2021 Aug 25; 22(8):1081-1092. PubMed ID: 34252374
    [Abstract] [Full Text] [Related]

  • 9. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
    Jiang Z, Xie Y, Zhang W, Du C, Zhong Y, Zhu Y, Jiang L, Dou L, Shao K, Sun Y, Xue Q, Tian Y, Gao S, Zhao D, Zhou A.
    Gastric Cancer; 2024 May 25; 27(3):571-579. PubMed ID: 38457083
    [Abstract] [Full Text] [Related]

  • 10. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y, Wang Q, Wang J, Qiao XY, Zhang J, Lin YC, Li Y, Fan LQ, Yang PG, Zhao Q.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):128-137. PubMed ID: 33508918
    [Abstract] [Full Text] [Related]

  • 11. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
    Shi JM, Li N, Jiang LM, Yang L, Wang SL, Song YW, Liu YP, Fang H, Lu NN, Qi SN, Chen B, Li YX, Zhao DB, Tang Y, Jin J.
    Sci Rep; 2024 Mar 29; 14(1):7522. PubMed ID: 38553594
    [Abstract] [Full Text] [Related]

  • 12. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
    Wu L, Yan H, Qin Y, Huang M, Wang T, Jin Q, Wei W.
    BMJ Open; 2024 Feb 10; 14(2):e075696. PubMed ID: 38341203
    [Abstract] [Full Text] [Related]

  • 13. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X, Jin J, Cai H, Huang H, Zhao G, Zhou Y, Wu J, Du C, Long Z, Fang Y, Ma M, Li G, Zhou M, Yin J, Zhu X, Zhu J, Sheng W, Huang D, Zhu H, Zhang Z, Lu Q, Xie L, Zhang Z, Wang Y.
    BMC Cancer; 2019 Jun 20; 19(1):606. PubMed ID: 31221115
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, Kim HJ, Jung HY, Lee GH, Kim KC, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2013 Oct 20; 72(4):815-23. PubMed ID: 23921575
    [Abstract] [Full Text] [Related]

  • 15. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V.
    Int J Cancer; 2015 Aug 01; 137(3):678-85. PubMed ID: 25530271
    [Abstract] [Full Text] [Related]

  • 16. ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Sun X, Lyu J, Yin Y, Tao K.
    Ann Surg Oncol; 2024 Nov 01; 31(12):8179-8180. PubMed ID: 39212861
    [No Abstract] [Full Text] [Related]

  • 17. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
    Sun W, Veeramachaneni N, Al-Rajabi R, Madan R, Kasi A, Al-Kasspooles M, Baranda J, Saeed A, Phadnis MA, Godwin AK, Olyaee M, Streeter N, Nagji A, Dai J, Williamson S.
    Cancer Med; 2023 Aug 01; 12(15):16098-16107. PubMed ID: 37326317
    [Abstract] [Full Text] [Related]

  • 18. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
    Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT.
    Oncologist; 2019 Apr 01; 24(4):475-482. PubMed ID: 30470690
    [Abstract] [Full Text] [Related]

  • 19. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F.
    BMC Cancer; 2019 May 24; 19(1):494. PubMed ID: 31126258
    [Abstract] [Full Text] [Related]

  • 20. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X, Li S, Sun Y, Li K, Shen X, Xue Y, Liang P, Li G, Chen L, Zhao Q, Li G, Fu W, Liang H, Xin H, Suo J, Fang X, Zheng Z, Xu Z, Chen H, Zhou Y, He Y, Huang H, Zhu L, Yang K, Ji J, Ye Y, Zhang Z, Li F, Wang X, Tian Y, Park S, Chen L.
    BMC Cancer; 2021 Jan 05; 21(1):20. PubMed ID: 33402102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.